We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
신규 편입 · 포트폴리오 비중 0.00%
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
US analyst rating / recommendation change.
Consensus vs. actual, and revenue trend
Consensus PT $15.33 · 6 analysts
CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge - Stocktwits
CRMD Stock Soared 18% Today – Here’s What Fueled CorMedix’s Triple-Digit Q1 Revenue Surge Stocktwits
CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market - Stocktwits
CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market Stocktwits
Enterprise value to revenue forward of CorMedix Inc. – NASDAQ:CRMD - TradingView
Enterprise value to revenue forward of CorMedix Inc. – NASDAQ:CRMD TradingView
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
Exelixis, Inc. (EXEL) Hit a 52 Week High, Can the Run Continue?
RBC Capital Trims CorMedix Price Target to $13 From $14, Maintains Outperform Rating
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| — | 2026. 08. 06. | After market close (AMC) | $0.27 | — | — | $94.95M | — | Scheduled |
| FY2026 Q1 | 2025. 03. 31. | Time TBD | — | $0.3 | — | — | $39.08M | Reported |
| FY2025 Q1 | 2025. 03. 31. | Time TBD | — | $-0.25 | — | — | $39.08M | Reported |
| FY2024 Q3 | 2024. 09. 30. | Time TBD | — | $-0.65 | — | — | $12.26M | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 04. 28. | RBC Capital | — | Maintain | Outperform → Outperform | — | RBC Capital: Outperform |
| 2026. 04. 28. | Citizens | — | Maintain | Market Outperform → Market Outperform | — | Citizens: Market Outperform |
| 2026. 04. 28. | Leerink Partners | — | Maintain | Outperform → Outperform | — | Leerink Partners: Outperform |
| 2026. 04. 28. | Needham | — | Maintain | Buy → Buy | — | Needham: Buy |
| 2026. 04. 27. | D. Boral Capital | — | Maintain | Buy → Buy | — | D. Boral Capital: Buy |
| 2026. 03. 05. | Needham | — | Maintain | Buy → Buy | — | Needham: Buy |
As of FY2026Q1 · Source: SEC/DART + price data
| # | Institution | Mandate | Shares | Value | Weight | Change | Position |
|---|---|---|---|---|---|---|---|
| 1 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 181,106 | $2.11M | 0.00% | — | New position |
| 2 | TWO SIGMA INVESTMENTS, LP | TWO SIGMA INVESTMENTS, LP | 20,588 | $139.79K | 0.00% | — | New position |